Destination
Eli Lilly is losing market share as generic weight loss drugs flood the market in India

Diabetes affects roughly 100 million people in India, and approximately one in four Indians carries excess weight [...]

Rating

Innovation

Pricing

Technology

Usability

We have discovered similar tools to what you are looking for. Check out our suggestions for similar AI tools.

Destination
Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug study

Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — and Eli Lilly’s drug came out on top.Read more... [...]

Match Score: 116.13

Destination
Eli Lilly is stepping up its fight against copycat weight-loss drugs

In its continuing war against copycat drugs, Eli Lilly (LLY) said on Wednesday that it filed suits against four telehealth companies that offer cheaper versions of its blockbuster GLP-1 weight loss dr [...]

Match Score: 103.72

Destination
Doctor Who: ‘The Interstellar Song Contest’ review: Camp!

Spoilers for “The Interstellar Song Contest.”<br /> <br /> No, really, spoilers from here on out.<br /> <br /> Much like Eurovision itself, that was a lot, wasn’t it?< [...]

Match Score: 93.50

Destination
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race

Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant consistently led the pack in new prescriptions, becoming virtually synonymous w [...]

Match Score: 92.87

thenextweb
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy

London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biot [...]

Match Score: 92.37

Destination
An Ozempic successor falls short, Eli Lilly's GLP-1 pill, and senators grill RFK: Pharma news roundup

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as it would be easier to manufacture and distribute globally. Three U.S. sen [...]

Match Score: 88.86

Destination
Eli Lilly's online health platform just expanded beyond weight loss to tackle Alzheimer’s

Just about a year after launching a direct-to-consumer online platform to sell treatments for diabetes and obesity, Eli Lilly (LLY) is now expanding the program to offer resources for Alzheimer’s d [...]

Match Score: 83.90

Destination
Eli Lilly's first weight-loss pill could expand access to GLP-1s around the globe, executive says

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.Read more... [...]

Match Score: 81.85

Destination
Eli Lilly signs $2.75 billion deal with AI drug developer Insilico Medicine

US pharmaceutical giant Eli Lilly is betting big on AI-driven drug development, signing a $2.75 billion deal with Hong Kong-listed Insilico Medicine.<br /> The article Eli Lilly signs $2.75 bill [...]

Match Score: 77.40